secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001628280-24-000762
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn outlines 2024 pipeline milestones; AML combo data expected H2, six INDs over four years
--------------------------------------------------------------------------------

- FHD-286 Phase 1 combination study in AML continues; first data expected H2 2024.
- Preclinical combo data with TKIs in EGFR/KRAS resistance expected Q2 2024.
- Selective EP300 and CBP degraders show efficacy without thrombocytopenia; CBP IND enabling studies targeted before end of 2024.
- At least six new INDs planned over next four years across >20 tumor types.
- Cash $259.9M as of Sep 30, 2023; runway into H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828024000762/0001628280-24-000762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828024000762/fhtx-20240108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-000762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer